The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma
Open accessAbstract
Background: The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibitor sirolimus can improve hepatocellular carcinoma (HCC)-free patient survival in liver transplant (LT) recipients with a pre-transplant diagnosis of HCC. Methods/Design: The study is an open-labelled, randomised, RCT comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing LT for HCC. Patients with a histologically confirmed HCC diagnosis are randomised into 2 groups within 4-6 weeks after LT; one arm is maintained on a centre-specific mTOR-inhibitor-free immunosuppressive protocol and the second arm is maintained on a centre-specific mTOR-inhibitor-free immunosuppressive protocol for the first 4-6 weeks, at which time sirolimus is initiated. A 2 1/2 -year recruitment phase is planned with a 5-year follow-up, testing HCC-free survival as the primary endpoint. Our hypothesis is that sirolimus use in the second arm of the study will improve HCC-free survival. The study is a non-commercial investigator-initiated trial (IIT) sponsored by the University Hospital Regensburg and is endorsed by the European Liver and Intestine Transplant Association; 13 countries within Europe, Canada and Australia are participating. Discussion: If our hypothesis is correct that mTOR inhibition can reduce HCC tumour growth while simultaneously providing immunosuppression to protect the liver allograft from rejection, patients should experience less post-transplant problems with HCC recurrence, and therefore could expect a longer and better quality of life. A positive outcome will likely change the standard of posttransplant immunosuppressive care for LT patients with HCC. Trial Register: Trial registered at http://www.clinicaltrials.gov: NCT00355862 (EudraCT Number: 2005-005362-36)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · cited 1×
“From a clinical perspective, mTOR inhibitors have begun to show efficacy with some types of cancer, including especially advanced renal cell carcinoma [13, 14 ].”
Cited by
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
EASL Clinical Practice Guidelines: Liver transplantation
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.006 · Cited by 1,082
Liver Transplantation for Nonresectable Liver Metastases From Colorectal Cancer
Hagness, M., Foss, A., Line, P.-D., Scholz, T., Jørgensen, P. F., Fosby, B., Boberg, K. M., Mathisen, Ø., Gladhaug, I. P., Egge, T. S., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e3182823957 · Cited by 464
Self-citationHepatocellular Carcinoma: Current Management and Perspectives for the Future
Rahbari, N. N., Mehrabi, A., Mollberg, N. M., Müller, S. A., Koch, M., Büchler, M. W., & Weitz, J. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e31820d944f · Cited by 453
Metadata
- Authors
- Schnitzbauer, A. A., Zuelke, C., Graeb, C., Rochon, J., Bilbao, I., Burra, P., de Jong, K. P., Duvoux, C., Kneteman, N. M., Adam, R., Bechstein, W. O., Becker, T., Beckebaum, S., Chazouillères, O., Cillo, U., Colledan, M., Fändrich, F., Gugenheim, J., Hauss, J. P., Heise, M., Hidalgo, E., Jamieson, N., Königsrainer, A., Lamby, P. E., Lerut, J. P., Mäkisalo, H., Margreiter, R., Mazzaferro, V., Mutzbauer, I., Otto, G., Pageaux, G.-P., Pinna, A. D., Pirenne, J., Rizell, M., Rossi, G., Rostaing, L., Roy, A., Turrion, V. S., Schmidt, J., Troisi, R. I., van Hoek, B., Valente, U., Wolf, P., Wolters, H., Mirza, D. F., Scholz, T., Steininger, R., Soderdahl, G., Strasser, S. I., Jauch, K.-W., Neuhaus, P., Schlitt, H. J., & Geissler, E. K.
- Venue
- BMC Cancer
- Published
- 2010-05-11
- Volume
- 10
- Issue
- 1
- Pages
- 190-190
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W2143386010
- Cited by
- 161
- References
- 1
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. https://app.cochat.ai/papers/10.1186/1471-2407-10-190
- The paper
- Schnitzbauer, A. A., Zuelke, C., Graeb, C., Rochon, J., Bilbao, I., Burra, P., de Jong, K. P., Duvoux, C., Kneteman, N. M., Adam, R., Bechstein, W. O., Becker, T., Beckebaum, S., Chazouillères, O., Cillo, U., Colledan, M., Fändrich, F., Gugenheim, J., Hauss, J. P., . . . Geissler, E. K. (2010). A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer. https://doi.org/10.1186/1471-2407-10-190
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.